Biotechnology company developing biosimilar therapies for chronic inflammatory diseases and oncology.
Coherus BioSciences, Inc. is a dynamic biopharmaceutical company that specializes in the biosimilar and immuno-oncology markets, primarily operating within the United States. Established in 2010 and headquartered in Redwood City, California, Coherus BioSciences has carved a niche by delivering innovative treatments that aim to enhance patient access to critical therapies.
The company's flagship product, UDENYCA, is a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor, which is successfully marketed in the United States. Coherus BioSciences continues to expand its portfolio with a robust pipeline that includes biosimilars of key biologics such as Humira, Avastin, and Lucentis, offering cost-effective alternatives to patients and healthcare providers.
In addition to biosimilars, Coherus BioSciences is advancing proprietary therapies globally. This includes Toripalimab, a novel anti-PD-1 antibody developed for second-line treatment of melanoma in China, and biosimilars for Bevacizumab (Avastin), adalimumab (CHS-1420), and ranibizumab (Lucentis). These developments underscore the company's commitment to addressing critical medical needs across diverse therapeutic areas.
Collaboration lies at the heart of Coherus BioSciences' strategy, as evidenced by its partnerships with industry leaders such as Selexis SA, AbbVie, Inc., Pfizer, Inc., Bioeq AG, Innovent Biologics (Suzhou) Co., Ltd., and Junshi Biosciences. These alliances facilitate the advancement of innovative therapies and ensure strategic growth in the competitive biopharmaceutical landscape. With a steadfast dedication to innovation and patient-centric care, Coherus BioSciences continues to drive forward its mission of improving global healthcare outcomes.